Literature DB >> 3890093

Invasive pneumococcal infections: incidence, predisposing factors, and prognosis.

L A Burman, R Norrby, B Trollfors.   

Abstract

A retrospective analysis of the case records of 494 patients with 508 episodes of pneumococcal infections verified by cultures from blood or from cerebrospinal, pleural, and/or synovial fluid from 1964 through 1980 is presented and discussed in relation to the literature on invasive pneumococcal infections. The documented incidence (1976-1980) of pneumococcal meningitis in a defined area of southwestern Sweden was similar to that reported from the United States; 1.4 cases per 100,000 persons per year; for nonmeningitic infections (mainly bacteremic pneumonia) the incidence was 6.1 per 100,000 per year. The highest age-specific incidence was seen in infants younger than two years. In the vast majority of patients, predisposing conditions (young or old age or severe underlying diseases) were present. In adults, alcoholism was the most important risk factor. The fatality rate was 33% for patients with meningitis and 15% for patients with non-meningitic infections, figures that were strikingly similar to those reported in other studies. Underlying diseases and young or old age contributed significantly to the high mortality rates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890093     DOI: 10.1093/clinids/7.2.133

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  50 in total

1.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Multilocus sequence typing directly on DNA from clinical samples and a cultured isolate to investigate linked fatal pneumococcal disease in residents of a shelter for homeless men.

Authors:  Andrew Birtles; Noel McCarthy; Carmen L Sheppard; Harry Rutter; Malcolm Guiver; Elizabeth Haworth; Robert C George
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 3.  The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens.

Authors:  A Zandvoort; W Timens
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

4.  Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies.

Authors:  K Y Green; P H Dorsett
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays.

Authors:  T Zhang; C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

6.  Identification of new risk factors for pneumonia: population-based case-control study.

Authors:  Yana Vinogradova; Julia Hippisley-Cox; Carol Coupland
Journal:  Br J Gen Pract       Date:  2009-10       Impact factor: 5.386

7.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 8.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

9.  Pneumococcal community-acquired pneumonia in 148 hospitalized adult patients.

Authors:  A Porath; F Schlaeffer; N Pick; M Leinonen; D Lieberman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

10.  Differences in clinical manifestation of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids.

Authors:  Annette Spreer; Astrid Lis; Joachim Gerber; Ralf René Reinert; Helmut Eiffert; Roland Nau
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.